Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Cellectis Stock Quote

Cellectis (NASDAQ: CLLS)

$2.97
(5.7%)
$0.16
Price as of December 8, 2023, 4:00 p.m. ET

You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Cellectis Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
CLLS +32.59% -85.33% -31.85% -92%
S&P +16.57% +74.15% +11.73% +122%

Cellectis Company Info

Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.

News & Analysis

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.